Notice: Release of the revised Guidance Document: Post-Notice of Compliance (NOC) Changes – Safety and Efficacy

August 12, 2019

Our file number: 19-110903-997

Health Canada is pleased to announce the release of the revised Guidance Document: Post-Notice of Compliance (NOC) Changes - Safety and Efficacy.

The Guidance Document: Post-Notice of Compliance (NOC) Changes - Safety and Efficacy released in September 2009 provides a comprehensive guidance regarding the reporting categories for any post authorization change relating to safety and efficacy and recommendations for supporting documentation.

In June 2015, changes were made to reflect amendments to the Food and Drug Regulations: Regulations Amending the Food and Drug Regulations (Labelling, Packaging and Brand Names of Drugs for Human Use) which came into force on June 13, 2015 for prescription products and those administered or obtained through a health professional.

In February 2016, changes were made to reflect that, under the Plain Language Labelling requirements, Level II and Level III changes no longer require the submission of mock-ups.

In February 2018, administrative changes were made such as:

In addition, consequential changes have been made over the past several years to include new initiatives that have been implemented such as:

This version of the guidance reflects the following changes:

This guidance document becomes effective from the date of posting on the Health Canada website. Questions or concerns related to this guidance document should be directed to:

Bureau of Policy, Science and International Programs
Therapeutic Products Directorate
Health Canada
1600 Scott Street
Holland Cross, Tower B
2nd Floor, Address Locator 3102C1
Ottawa, Ontario
K1A 0K9

Facsimile: 613-941-1812
E-mail: hc.policy.bureau.enquiries.sc@canada.ca

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: